Health policy experts are concerned about FDA approval of Aduhelm--with its hefty price tag--for all Alzheimer's patients. CP3 Director Dr. Walid Gellad told Axios, “It’s always been the worry that if you get a super expensive drug that is targeted toward a huge population, that that is going to be a turning point in how we deal with health care spending. And that’s what this drug is.”